Herve Prats

Title: Herve Prats: Innovator in Anti-Angiogenic Research

Introduction

Herve Prats is a notable inventor based in Toulouse Cedex, France. He has made significant contributions to the field of anti-angiogenic research, holding a total of 2 patents. His work focuses on developing innovative solutions to combat diseases associated with pathological angiogenesis.

Latest Patents

One of his latest patents is titled "Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity." This invention pertains to PF4 muteins that include a substitution at position 67, such as a L67H substitution, compared to the wild-type PF4 protein. These PF4 muteins demonstrate enhanced anti-angiogenic activity and a reduced affinity for proteoglycans when compared to the wild-type PF4 protein. Another significant patent is "Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (PF4V1)." This invention relates to neutralizing antibodies and fragments aimed at Platelet Factor-4 variant 1 (PF4v1) and their application in treating conditions that necessitate the induction of angiogenesis or diseases linked to pathological angiogenesis.

Career Highlights

Herve Prats has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université de Bordeaux. His career reflects a commitment to advancing medical research and developing innovative therapeutic solutions.

Collaborations

Throughout his career, Prats has collaborated with notable colleagues, including Andreas Bikfalvi and Alexandre Dubrac. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Herve Prats is a distinguished inventor whose work in anti-angiogenic research has led to valuable patents that hold promise for treating various medical conditions. His contributions to the field continue to inspire innovation and collaboration in medical research.